nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04380688,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,2021-08-19,NA,2021-09-08,2020-05-07,2020-05-08,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-08,2021-09-13,Actual,"June 13, 2020",Actual,2020-06-13,September 2021,2021-09-30,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,CALAVI US,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,62,Actual,AstraZeneca,"Improvements in BSC (use of corticosteroids and antivirals) have led to a substantial reduction in mortality and morbidity in patients hospitalized with COVID-19, which, in turn, minimizes the impact that additional treatment regimens can have on patient prognosis and recovery. In addition, variability in patient population and the performance of BSC across the globe poses challenges to demonstrate benefit.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",2021-10-17T08:25:37Z,2021-10-17T08:25:37Z,52
NCT04365153,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,2021-04-05,NA,2021-04-13,2020-04-24,2020-04-28,Actual,2021-04-13,2021-04-15,Actual,NA,NA,NA,2021-04-13,2021-04-15,Actual,"April 24, 2020",Actual,2020-04-24,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation,Completed,NA,Phase 2,45,Actual,The Cleveland Clinic,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:57Z,2021-10-17T08:27:57Z,200
NCT04372186,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,2021-08-04,NA,2021-09-23,2020-04-29,2020-05-01,Actual,2021-09-23,2021-09-27,Actual,NA,NA,NA,2021-09-23,2021-09-27,Actual,"May 14, 2020",Actual,2020-05-14,September 2021,2021-09-30,"December 1, 2021",Anticipated,2021-12-01,"August 18, 2020",Actual,2020-08-18,NA,Interventional,EMPACTA,"mITT population = all randomized participants who received study treatment, grouped according to the treatment assigned at randomization. Participants not receiving study treatment were excluded from analyses.",A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,377,Actual,"Genentech, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-17T08:26:55Z,2021-10-17T08:26:55Z,37
NCT04371419,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,2021-05-28,NA,2021-07-24,2020-04-28,2020-05-01,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"May 13, 2020",Actual,2020-05-13,July 2021,2021-07-31,"May 26, 2020",Actual,2020-05-26,"May 24, 2020",Actual,2020-05-24,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,N/A,14267,Actual,"National Bureau of Economic Research, Inc.","Participants' behavior was not directly observed, outcomes were measured immediately postintervention in May 2020, and online recruitment may not be representative.",17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2021-10-17T08:27:01Z,2021-10-17T08:27:01Z,98
NCT04370834,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-30,2021-05-28,NA,2021-07-16,2020-04-30,2020-05-01,Actual,2021-05-28,2021-06-04,Actual,NA,NA,NA,2021-07-16,2021-07-20,Actual,"May 28, 2020",Actual,2020-05-28,July 2021,2021-07-31,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,,Tocilizumab for Patients With Cancer and COVID-19 Disease,Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19),Terminated,NA,Phase 2,1,Actual,National Cancer Institute (NCI),Early termination as randomized data did not support continuation.,1,NA,Other - Randomized data no longer support continuation,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://grants.nih.gov/policy/sharing.htm,Yes,"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.",2021-10-17T08:27:07Z,2021-10-17T08:27:07Z,106
NCT04365699,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-25,2021-09-01,NA,2021-09-10,2020-04-25,2020-04-28,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 8, 2020",Actual,2020-04-08,September 2021,2021-09-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,,Cardiovascular Effects of COVID-19,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection,Completed,NA,Phase 2,81,Actual,NYU Langone Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication,Requests may be directed to Stuart.Katz@nyulangone.org.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to Stuart.Katz@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-10-17T08:27:52Z,2021-10-17T08:27:52Z,50
NCT04363736,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,2021-07-30,NA,2021-08-26,2020-04-24,2020-04-27,Actual,2021-08-26,2021-08-30,Actual,NA,NA,NA,2021-08-26,2021-08-30,Actual,"May 5, 2020",Actual,2020-05-05,August 2021,2021-08-31,"August 12, 2020",Actual,2020-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,MARIPOSA,,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Completed,NA,Phase 2,97,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-17T08:28:10Z,2021-10-17T08:28:10Z,65
NCT04362813,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,2021-07-30,2021-02-08,2021-08-12,2020-04-24,2020-04-27,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,"April 30, 2020",Actual,2020-04-30,August 2021,2021-08-31,"December 22, 2020",Actual,2020-12-22,"September 16, 2020",Actual,2020-09-16,NA,Interventional,CAN-COVID,"While patient flow and baseline measure tables show 454 participants enrolled, only 451 randomized. 3 were ""mis-randomized"" i.e. assigned a randomization number in error and not treated.",Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)",Completed,NA,Phase 3,454,Actual,Novartis,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-10-17T08:28:18Z,2021-10-17T08:28:18Z,79
NCT04362137,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,2021-04-15,NA,2021-10-07,2020-04-22,2020-04-24,Actual,2021-05-28,2021-06-02,Actual,NA,NA,NA,2021-10-07,2021-10-11,Actual,"May 2, 2020",Actual,2020-05-02,October 2021,2021-10-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,RUXCOVID,,Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,NA,Phase 3,432,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-10-17T08:28:24Z,2021-10-17T08:28:24Z,23
NCT04358081,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2021-03-08,NA,2021-10-07,2020-04-20,2020-04-22,Actual,2021-03-08,2021-03-17,Actual,NA,NA,NA,2021-10-07,2021-10-11,Actual,"May 1, 2020",Actual,2020-05-01,October 2021,2021-10-31,"July 27, 2020",Actual,2020-07-27,"July 27, 2020",Actual,2020-07-27,NA,Interventional,NA,Full Analysis Set (FAS) was comprised of all participants to whom study treatment had been assigned by randomization excluding one mis-randomized participant.,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Completed,NA,Phase 3,20,Actual,Novartis,"Only 20 participants of the initially planned 444 were randomized; and one of those was mis-randomized (so total of 19 participants). Due to this limited number of participants, study objectives could not be evaluated as planned. Results for select efficacy and for safety were summarized based in the information collected up to the eCRF database lock on 13-Aug-2020.",3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-10-17T08:28:58Z,2021-10-17T08:28:58Z,23
NCT04356937,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-19,2021-06-23,NA,2021-07-23,2020-04-19,2020-04-22,Actual,2021-07-23,2021-07-27,Actual,NA,NA,NA,2021-07-23,2021-07-27,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"August 27, 2020",Actual,2020-08-27,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,All randomized patients,Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19,Completed,NA,Phase 3,243,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Request for IPD can be submitted to PI for review,2021-10-17T08:29:08Z,2021-10-17T08:29:08Z,99
NCT04354870,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,2021-09-29,NA,2021-10-04,2020-04-16,2020-04-21,Actual,2021-10-04,2021-10-06,Actual,NA,NA,NA,2021-10-04,2021-10-06,Actual,"April 3, 2020",Actual,2020-04-03,October 2021,2021-10-31,"October 1, 2020",Actual,2020-10-01,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Completed,NA,Phase 2,130,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,Study internal to NYU at this time,2021-10-17T08:29:26Z,2021-10-17T08:29:26Z,26
NCT04345653,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2021-04-01,NA,2021-05-10,2020-04-13,2020-04-14,Actual,2021-05-05,2021-05-10,Actual,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 14, 2020",Actual,2020-04-14,May 2021,2021-05-31,"May 10, 2021",Actual,2021-05-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,High risk healthcare providers,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers",Completed,NA,Phase 2,48,Actual,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:50Z,2021-10-17T08:30:50Z,173
NCT04343092,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-05,2020-06-11,NA,2020-11-02,2020-04-08,2020-04-13,Actual,2020-11-02,2020-11-04,Actual,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,"small sample size; single center design, and short time for the study",1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:12Z,2021-10-17T08:31:12Z,362
NCT04342897,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-10,2021-08-04,NA,2021-08-04,2020-04-10,2020-04-13,Actual,2021-08-04,2021-08-12,Actual,NA,NA,NA,2021-08-04,2021-08-12,Actual,"April 20, 2020",Actual,2020-04-20,August 2021,2021-08-31,"October 12, 2020",Actual,2020-10-12,"October 12, 2020",Actual,2020-10-12,NA,Interventional,NA,All randomized participants who received at least 1 dose of study drug.,A Study of LY3127804 in Participants With COVID-19,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",Terminated,NA,Phase 2,95,Actual,Eli Lilly and Company,The study was terminated for futility reason.,2,NA,Trial terminated for futility.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2021-10-17T08:31:13Z,2021-10-17T08:31:13Z,87
NCT04340557,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,2021-05-20,NA,2021-05-24,2020-04-08,2020-04-09,Actual,2021-05-24,2021-05-26,Actual,NA,NA,NA,2021-05-24,2021-05-26,Actual,"March 27, 2020",Actual,2020-03-27,May 2021,2021-05-31,"June 13, 2020",Actual,2020-06-13,"June 13, 2020",Actual,2020-06-13,NA,Interventional,NA,,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Completed,NA,Phase 4,31,Actual,Sharp HealthCare,"The generalizability is limited by small size of the study population, unblinded design, and all the subjects being screened from three hospitals in close proximity in one geographic area in Southern California.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:33Z,2021-10-17T08:31:33Z,159
NCT04338074,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,2021-04-21,NA,2021-05-11,2020-04-06,2020-04-08,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"June 1, 2020",Actual,2020-06-01,May 2021,2021-05-31,"April 21, 2021",Actual,2021-04-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,TCOutpatient,,TXA and Corona Virus 2019 (COVID19) in Outpatients,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients,Terminated,NA,Phase 2,5,Actual,University of Alabama at Birmingham,,2,NA,Lack of recruitment,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:58Z,2021-10-17T08:31:58Z,172
NCT04346199,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,2021-09-08,NA,2021-09-15,2020-04-14,2020-04-15,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-15,2021-09-17,Actual,"June 12, 2020",Actual,2020-06-12,September 2021,2021-09-30,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,CALAVI,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,177,Actual,AstraZeneca,"Improvements in BSC (use of corticosteroids and antivirals) have led to a substantial reduction in mortality and morbidity in patients hospitalized with COVID-19, which, in turn, minimizes the impact that additional treatment regimens can have on patient prognosis and recovery. In addition, variability in patient population and the performance of BSC across the globe poses challenges to demonstrate benefit.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2021-10-17T08:30:44Z,2021-10-17T08:30:44Z,45
NCT04343261,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:10Z,2021-10-17T08:31:10Z,403
NCT04342663,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2021-07-01,NA,2021-07-07,2020-04-08,2020-04-13,Actual,2021-07-07,2021-07-09,Actual,NA,NA,NA,2021-07-07,2021-07-09,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"December 12, 2020",Actual,2020-12-12,"August 20, 2020",Actual,2020-08-20,NA,Interventional,STOP COVID,,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,NA,Phase 2,152,Actual,Washington University School of Medicine,It was a small study and was conducted within a single geographic area; there was a small number of end point events; it is possible that the differences in clinical deterioration may have been a reflection of the comparative baseline distributions of O2 saturation rather than an effect of treatment; the method of measuring the most severe baseline symptom over time did not appear to provide valid data; the follow-up was short; the 7-point scale created for this study has not been validated.,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:31:15Z,2021-10-17T08:31:15Z,115
NCT04338009,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,2021-01-28,NA,2021-04-07,2020-04-07,2020-04-08,Actual,2021-04-07,2021-04-09,Actual,NA,NA,NA,2021-04-07,2021-04-09,Actual,"March 31, 2020",Actual,2020-03-31,April 2021,2021-04-30,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,REPLACECOVID,,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Completed,NA,N/A,152,Actual,University of Pennsylvania,"Limitations of the study include (1) small sample size; (2) we did not control participant ACEI or ARB dosing or other medication exposures during the trial; (3) Although outcome adjudicators were masked to the randomly assigned groups when determining clinical endpoints, providers caring for the patients were aware of the group the patient was assigned to. It is possible that the open-label nature of the study might have introduced information bias or influenced provider behavior.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Not making it available,2021-10-17T08:31:59Z,2021-10-17T08:31:59Z,206
NCT04335136,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,2021-06-07,NA,2021-07-29,2020-04-03,2020-04-06,Actual,2021-07-29,2021-08-02,Actual,NA,NA,NA,2021-07-29,2021-08-02,Actual,"April 30, 2020",Actual,2020-04-30,July 2021,2021-07-31,"December 26, 2020",Actual,2020-12-26,"December 26, 2020",Actual,2020-12-26,NA,Interventional,APN01-COVID-19,All randomized patients who received at least 1 dose of investigational medicinal product (IMP).,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,NA,Phase 2,185,Actual,Apeiron Biologics,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:32:26Z,2021-10-17T08:32:26Z,93
NCT04335552,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-03,2021-05-03,NA,2021-05-13,2020-04-03,2020-04-06,Actual,2021-05-03,2021-05-12,Actual,NA,NA,NA,2021-05-13,2021-05-17,Actual,"April 17, 2020",Actual,2020-04-17,May 2021,2021-05-31,"June 26, 2020",Actual,2020-06-26,"June 17, 2020",Actual,2020-06-17,NA,Interventional,NA,,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,NA,Phase 2,11,Actual,Duke University,,4,NA,"Poor recruitment, strong evidence from larger trials of no therapeutic benefit",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:22Z,2021-10-17T08:32:22Z,170
NCT04334876,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,2021-07-19,NA,2021-09-10,2020-04-02,2020-04-06,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"January 1, 2021",Actual,2021-01-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,COVID-Antibody,,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers and Candidacy for Convalescent Plasma Therapy/Prophylaxis,Completed,NA,N/A,571,Actual,Indiana University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:31Z,2021-10-17T08:32:31Z,50
NCT04333225,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,2021-08-02,NA,2021-08-18,2020-04-02,2020-04-03,Actual,2021-08-18,2021-08-20,Actual,NA,NA,NA,2021-08-18,2021-08-20,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,Completed,NA,Phase 2,221,Actual,Baylor Research Institute,"Due to the off-label use of HCQ, we were not able to incorporate randomization in our design.
The outcome of CLI was based on self-reported symptoms, which is prone to bias.
The trial may be under-powered as recruitment was forced to stop early at 221 instead of 360 because of the demand for and subsequent shortage of HCQ in March 2020.
Our study participants were young and healthy compared to other prophylaxis trials, which may partially explain the low rates of COVID-19.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:46Z,2021-10-17T08:32:46Z,73
NCT04332991,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,2021-02-09,NA,2021-03-12,2020-03-31,2020-04-03,Actual,2021-03-12,2021-03-17,Actual,NA,NA,NA,2021-03-12,2021-03-17,Actual,"April 2, 2020",Actual,2020-04-02,March 2021,2021-03-31,"July 23, 2020",Actual,2020-07-23,"June 19, 2020",Actual,2020-06-19,NA,Interventional,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,NA,Phase 3,479,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:32:49Z,2021-10-17T08:32:49Z,232
NCT04331899,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,2021-04-08,NA,2021-05-19,2020-04-01,2020-04-02,Actual,2021-04-19,2021-04-22,Actual,NA,NA,NA,2021-05-19,2021-05-21,Actual,"April 25, 2020",Actual,2020-04-25,May 2021,2021-05-31,"May 6, 2021",Actual,2021-05-06,"August 14, 2020",Actual,2020-08-14,NA,Interventional,COVID-Lambda,,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19",Completed,NA,Phase 2,120,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository,Full access,https://purl.stanford.edu/hc972ys6733,Yes,Sharing of generated and analyzed datasets.,2021-10-17T08:33:04Z,2021-10-17T08:33:04Z,164
NCT04332107,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,2021-08-09,NA,2021-10-05,2020-04-01,2020-04-02,Actual,2021-08-31,2021-09-09,Actual,NA,NA,NA,2021-10-05,2021-10-07,Actual,"May 22, 2020",Actual,2020-05-22,October 2021,2021-10-31,"March 30, 2021",Actual,2021-03-30,"March 16, 2021",Actual,2021-03-16,NA,Interventional,ACTION,A single participant in the Azithromycin group did not have baseline symptom information.,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19,Terminated,NA,Phase 3,263,Actual,"University of California, San Francisco","This trial was terminated early by the DSMC for futility on March 16, 2021. Therefore, we were not able to complete the analysis for all secondary outcomes because funds were returned to the sponsor following the completion of the study.
Please note that the number of participants varies by period as participants could opt to complete some questionnaires but not others. For example, a participant may skip the day 3 questionnaire, but complete the day 14 questionnaire.",2,NA,Futility,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:33:01Z,2021-10-17T08:33:01Z,25
NCT04332081,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,2021-06-14,NA,2021-06-16,2020-04-01,2020-04-02,Actual,2021-06-16,2021-06-22,Actual,NA,NA,NA,2021-06-16,2021-06-22,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"May 29, 2020",Actual,2020-05-29,"May 29, 2020",Actual,2020-05-29,NA,Interventional,NA,,Hyperbaric Oxygen for COVID-19 Patients,Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19,Terminated,NA,N/A,80,Actual,NYU Langone Health,,2,NA,"The IRB has determined that the design of this trial should be changed to a randomized
    controlled trial. A new record will be created for the redesigned study.",FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,Immediately following publication. No end date.,"Requests should be directed to David.Lee@nyulangone.org and Scott.Gorenstein@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be made available immediately following publication, upon reasonable request by an investigator who proposes to use the data.",2021-10-17T08:33:02Z,2021-10-17T08:33:02Z,136
NCT04331366,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,2021-02-05,NA,2021-02-16,2020-03-31,2020-04-02,Actual,2021-02-05,2021-02-10,Actual,NA,NA,NA,2021-02-16,2021-02-18,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,GO2 PEEP,,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,NA,N/A,2,Actual,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:10Z,2021-10-17T08:33:10Z,256
NCT04329923,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,2020-11-13,NA,2020-12-08,2020-03-30,2020-04-01,Actual,2020-12-08,2020-12-10,Actual,NA,NA,NA,2020-12-08,2020-12-10,Actual,"April 9, 2020",Actual,2020-04-09,December 2020,2020-12-31,"November 13, 2020",Actual,2020-11-13,"November 11, 2020",Actual,2020-11-11,NA,Interventional,PATCH,All randomized patients,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,NA,Phase 2,173,Actual,University of Pennsylvania,Sub-study 1 was terminated early after the first interim analysis due to slow accrual Sub-study 2 was terminated early after the first 7 patients based on the recommendation of UPenn research oversight committees Sub-study 3 was terminated early due to meeting futility criteria on a pre-specified second interim analysis,6,NA,"Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met
    pre-specificied futility analysis at planned second interim analysis",FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,One year after study completion,Open access,NA,Yes,We will publish our results in a peer-reviewed journal and make available de-identified data for additional analysis,2021-10-17T08:33:22Z,2021-10-17T08:33:22Z,326
NCT04328467,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,2021-06-25,NA,2021-06-30,2020-03-30,2020-03-31,Actual,2021-06-25,2021-06-30,Actual,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"July 13, 2020",Actual,2020-07-13,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1483,Actual,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:33:34Z,2021-10-17T08:33:34Z,122
NCT04327388,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,2021-04-28,NA,2021-05-11,2020-03-26,2020-03-31,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 28, 2020",Actual,2020-03-28,May 2021,2021-05-31,"September 2, 2020",Actual,2020-09-02,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,Analysis was performed on randomized population.,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T08:33:44Z,2021-10-17T08:33:44Z,172
NCT04322682,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,2021-08-10,NA,2021-09-03,2020-03-25,2020-03-26,Actual,2021-09-03,2021-09-08,Actual,NA,NA,NA,2021-09-03,2021-09-08,Actual,"March 23, 2020",Actual,2020-03-23,September 2021,2021-09-30,"January 21, 2021",Actual,2021-01-21,"January 21, 2021",Actual,2021-01-21,NA,Interventional,COVID-19,Characteristics of the patients at randomisation in the intent-to-treat population.,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Terminated,NA,Phase 3,4506,Actual,Montreal Heart Institute,"Due to several considerations (logistical, human and budgetary), the study was stopped early. Furthermore, stopping the study after approximately 4500 patients had completed their 30-day follow-up would allow to communicate results in January 2021 in the hope of preventing complications of COVID-19 in ambulatory patients, instead of delivering results anywhere between April and October 2021 at a time when vaccination efforts might be successful.",2,NA,"Due to several considerations (logistical, human and budgetary), the study was stopped early.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:34:26Z,2021-10-17T08:34:26Z,57
NCT04322396,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,2021-06-15,NA,2021-06-28,2020-03-24,2020-03-26,Actual,2021-06-24,2021-06-28,Actual,NA,NA,NA,2021-06-28,2021-06-29,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,ProPAC-COVID,,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,"Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Terminated,NA,Phase 2,117,Actual,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",Early termination based on recommendations from the DSMB leading to small numbers of subjects analyzed.,2,NA,Recommended by the DSMB,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:34:30Z,2021-10-17T08:34:30Z,124
NCT04320615,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,2021-06-23,NA,2021-06-28,2020-03-23,2020-03-25,Actual,2021-06-28,2021-06-30,Actual,NA,NA,NA,2021-06-28,2021-06-30,Actual,"April 3, 2020",Actual,2020-04-03,June 2021,2021-06-30,"July 28, 2020",Actual,2020-07-28,"June 24, 2020",Actual,2020-06-24,NA,Interventional,COVACTA,,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,452,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.
Further details on Roche's criteria for eligible studies are available here: https://vivli.org.
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2021-10-17T08:34:47Z,2021-10-17T08:34:47Z,124
NCT04317040,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-19,2021-09-28,NA,2021-10-13,2020-03-19,2020-03-20,Actual,2021-10-13,2021-10-15,Estimate,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"April 24, 2020",Actual,2020-04-24,October 2021,2021-10-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,SAC-COVID,All randomized participants.,CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007),"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Completed,NA,Phase 3,234,Actual,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-10-17T08:35:20Z,2021-10-17T08:35:20Z,17
NCT04315298,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-15,2021-07-23,NA,2021-09-16,2020-03-17,2020-03-19,Actual,2021-09-16,2021-09-23,Actual,NA,NA,NA,2021-09-16,2021-09-23,Actual,"March 18, 2020",Actual,2020-03-18,September 2021,2021-09-30,"September 2, 2020",Actual,2020-09-02,"July 24, 2020",Actual,2020-07-24,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Completed,NA,Phase 2/Phase 3,1912,Actual,Regeneron Pharmaceuticals,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All IPD that underlie publicly available results will be considered for sharing,2021-10-17T08:35:37Z,2021-10-17T08:35:37Z,44
NCT04308668,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-11,2021-04-26,NA,2021-05-11,2020-03-11,2020-03-16,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 17, 2020",Actual,2020-03-17,May 2021,2021-05-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1312,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,Yes,De-identified dataset will be available within 1 month of publication.,2021-10-17T08:36:47Z,2021-10-17T08:36:47Z,172
NCT04292899,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-28,2020-12-15,NA,2020-12-15,2020-02-28,2020-03-03,Actual,2020-12-15,2020-12-31,Actual,NA,NA,NA,2020-12-15,2020-12-31,Actual,"March 6, 2020",Actual,2020-03-06,December 2020,2020-12-31,"June 30, 2020",Actual,2020-06-30,"April 9, 2020",Actual,2020-04-09,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.
Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into part B of the study and received at least 1 dose of study treatment.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Completed,NA,Phase 3,4891,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-10-17T08:39:05Z,2021-10-17T08:39:05Z,319
NCT04292730,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-28,2020-12-15,NA,2021-01-21,2020-02-28,2020-03-03,Actual,2021-01-21,2021-01-26,Actual,NA,NA,NA,2021-01-21,2021-01-26,Actual,"March 15, 2020",Actual,2020-03-15,January 2021,2021-01-31,"June 26, 2020",Actual,2020-06-26,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).
Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Completed,NA,Phase 3,1113,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-10-17T08:39:08Z,2021-10-17T08:39:08Z,282
NCT04280705,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-20,2020-09-16,NA,2020-12-05,2020-02-20,2020-02-21,Actual,2020-09-22,2020-09-25,Actual,NA,NA,NA,2020-12-05,2020-12-09,Actual,"February 21, 2020",Actual,2020-02-21,April 2020,2020-04-30,"May 21, 2020",Actual,2020-05-21,"May 21, 2020",Actual,2020-05-21,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:41:02Z,2021-10-17T08:41:02Z,329
NCT04355767,"ClinicalTrials.gov processed this data on October 19, 2021",2020-04-17,2021-10-13,NA,2021-10-15,2020-04-17,2020-04-21,Actual,2021-10-15,2021-10-19,Estimate,NA,NA,NA,2021-10-15,2021-10-19,Estimate,"August 11, 2020",Actual,2020-08-11,October 2021,2021-10-31,"March 29, 2021",Actual,2021-03-29,"March 29, 2021",Actual,2021-03-29,NA,Interventional,C3PO,,Convalescent Plasma in Outpatients With COVID-19,Clinical-trial of COVID-19 Convalescent Plasma in Outpatients,Completed,NA,Phase 3,511,Actual,Stanford University,This study did not meet its maximum sample size of 900 participants due to a planned interim analysis that indicated that it was unlikely that there would be a difference in the rate of disease progression between the two groups if continued to the planned sample size.,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Data will be available indefinitely.,"Data requests will be managed by National Heart, Lung, and Blood Institute (NHLBI).",https://biodatacatalyst.nhlbi.nih.gov/,Yes,The complete de-identified patient data set will be shared.,2021-10-20T09:43:46Z,2021-10-20T09:43:46Z,15
NCT04353037,"ClinicalTrials.gov processed this data on October 19, 2021",2020-04-09,2021-07-22,NA,2021-10-15,2020-04-15,2020-04-20,Actual,2021-10-15,2021-10-19,Estimate,NA,NA,NA,2021-10-15,2021-10-19,Estimate,"April 7, 2020",Actual,2020-04-07,October 2021,2021-10-31,"July 11, 2020",Actual,2020-07-11,"July 11, 2020",Actual,2020-07-11,NA,Interventional,NA,All eligible randomized patients,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19,Terminated,NA,Phase 2,39,Actual,UnitedHealth Group,"No healthcare workers had a positive Covid test during the study period so the outcome for missed shifts due a positive Covid result was not measured.
Due to low enrollment numbers, only a descriptive analysis was reported and we did not test any of the hypotheses described in the statistical analysis plan.",2,NA,"As enrollment began external studies called into question the safety and efficacy of
    hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy
    significantly impacted our ability to enroll and retain participants.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,1 year,NA,NA,Yes,Data will be collected and managed by Optumcare and UnitedHealth Group Research & Development. Redacted/aggregate data will be shared with the University Of Penn using approved data sharing protocols.,2021-10-20T09:43:50Z,2021-10-20T09:43:50Z,15
NCT04347954,"ClinicalTrials.gov processed this data on October 21, 2021",2020-04-13,2021-10-15,NA,2021-10-19,2020-04-13,2020-04-15,Actual,2021-10-19,2021-10-21,Estimate,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"August 15, 2020",Actual,2020-08-15,October 2021,2021-10-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Interventional,NA,Participants who received the allocated intervention and completed the study; participants with negative PCR nasal swab results at baseline or incomplete data were excluded.,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Completed,NA,Phase 1/Phase 2,47,Actual,Stanford University,The study did not meet its accrual goal of 45 participants with analyzable data.,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-22T09:39:05Z,2021-10-22T09:39:05Z,11
NCT04504032,"ClinicalTrials.gov processed this data on October 22, 2021",2020-08-05,2021-09-29,NA,2021-10-20,2020-08-05,2020-08-07,Actual,2021-10-20,2021-10-22,Estimate,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"September 2, 2020",Actual,2020-09-02,October 2021,2021-10-31,"March 29, 2021",Actual,2021-03-29,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),"A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (XareltoÂ®) for High Risk People With Mild COVID-19",Terminated,NA,Phase 2,497,Actual,Bill & Melinda Gates Medical Research Institute,"Based on Data Monitoring Committee's recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.",2,NA,"Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped
    on 4 February 2021 due to futility.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-25T09:01:56Z,2021-10-25T09:01:56Z,10
NCT04558125,"ClinicalTrials.gov processed this data on October 26, 2021",2020-09-19,2021-09-21,NA,2021-10-20,2020-09-21,2020-09-22,Actual,2021-10-20,2021-10-26,Estimate,NA,NA,NA,2021-10-20,2021-10-26,Estimate,"September 8, 2020",Actual,2020-09-08,October 2021,2021-10-31,"August 8, 2021",Actual,2021-08-08,"July 10, 2021",Actual,2021-07-10,NA,Interventional,NA,"The study was terminated early and never unblinded. With only 2 subjects, statistical significance could never be demonstrated. Therefore, Arm/Group randomization information is not available.",Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,"Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial",Terminated,NA,Phase 4,2,Actual,Cedars-Sinai Medical Center,"The study was terminated early due to enrollment being slower than anticipated, with study enrollment highly dependent upon COVID-19 surge patterns. We were otherwise hopeful to enroll and complete all assessments for this study.",2,NA,Identification of eligible patients was slower than anticipated.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-27T11:18:25Z,2021-10-27T11:18:25Z,10
NCT04381988,"ClinicalTrials.gov processed this data on October 27, 2021",2020-05-08,2021-10-25,NA,2021-10-25,2020-05-08,2020-05-11,Actual,2021-10-25,2021-10-27,Estimate,NA,NA,NA,2021-10-25,2021-10-27,Estimate,"May 7, 2020",Actual,2020-05-07,April 2021,2021-04-30,"April 21, 2021",Actual,2021-04-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,NA,The study was terminated before more participants were accrued.,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID),Terminated,NA,Phase 2,4,Actual,Memorial Sloan Kettering Cancer Center,,2,NA,The study was terminated based results of other studies and use of the new vaccine.,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-10-28T09:14:16Z,2021-10-28T09:14:16Z,5
NCT04418947,"ClinicalTrials.gov processed this data on October 28, 2021",2020-05-29,2021-10-25,NA,2021-10-26,2020-06-02,2020-06-05,Actual,2021-10-26,2021-10-28,Estimate,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"June 15, 2020",Actual,2020-06-15,October 2021,2021-10-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,NA,Interventional,NA,,Project Resurgence Communication Trial,Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial,Completed,NA,N/A,11120,Actual,University of Pennsylvania,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-29T09:15:18Z,2021-10-29T09:15:18Z,4
NCT04484207,"ClinicalTrials.gov processed this data on October 28, 2021",2020-07-21,2021-10-12,NA,2021-10-26,2020-07-21,2020-07-23,Actual,2021-10-26,2021-10-28,Estimate,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"July 6, 2020",Actual,2020-07-06,October 2021,2021-10-31,"October 26, 2020",Actual,2020-10-26,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,,Addressing COVID-19 Mental Health Problems Among US Veterans,Addressing COVID-19 Mental Health Problems Among US Veterans,Completed,NA,N/A,172,Actual,"Research Foundation for Mental Hygiene, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,two months,Co-Is,NA,Yes,"Data will be shared as needed with investigators, IRB etc. A plan will be determined in the short future",2021-10-29T09:15:07Z,2021-10-29T09:15:07Z,4
NCT04358068,"ClinicalTrials.gov processed this data on October 28, 2021",2020-04-20,2021-02-24,NA,2021-10-26,2020-04-20,2020-04-22,Actual,2021-03-24,2021-04-01,Actual,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"May 13, 2020",Actual,2020-05-13,October 2021,2021-10-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,Participants who initiated study treatment,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,"A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",Terminated,NA,Phase 2,20,Actual,National Institute of Allergy and Infectious Diseases (NIAID),The study was terminated early due to slow enrollment and lack of community enthusiasm. Follow-up through week 24 was not completed for any participant. Participants were asked to complete the Day 20 visit and then were discontinued from the study.,2,NA,Slow enrollment and lack of community enthusiasm,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom?
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses?
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available?
Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-10-29T09:15:43Z,2021-10-29T09:15:43Z,4
NCT04871815,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-27,2021-09-27,NA,2021-10-05,2021-04-30,2021-05-04,Actual,2021-10-05,2021-10-07,Actual,NA,NA,NA,2021-10-05,2021-10-07,Actual,"April 27, 2021",Actual,2021-04-27,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,,Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.,Preliminary Examination of the Effects of Sodium Pyruvate Nasal Spray (N115) on Symptoms Associated With COVID19 Long Haulers.,"Active, not recruiting",NA,Phase 2/Phase 3,22,Actual,"Cellular Sciences, inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:09:38Z,2021-10-17T07:09:38Z,25
NCT04732819,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-27,2021-07-22,NA,2021-09-01,2021-01-29,2021-02-01,Actual,2021-09-01,2021-09-05,Actual,NA,NA,NA,2021-09-01,2021-09-05,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"April 16, 2021",Actual,2021-04-16,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,"The overall number of baseline participants includes the number of residents and staff in each arm. The unit analyzed was nursing home facility. Baseline characteristics were obtained for residents and nursing home facilities, but not for staff.",Improving COVID-19 Vaccine Uptake in Nursing Homes,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities,Completed,NA,N/A,23768,Actual,Brown University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The IPD and supporting documentation will be available through the CDCC within 6 months of the completion of the trial.,"Staff and patient data will be aggregated at the level of the facility. This data will be shared with the RADx-UP CDCC, who plans to make a central database that will ultimately be publicly available.",NA,Yes,"Data will be aggregated at the level of the facility. We will provide aggregated data to the RADx-UP Coordination and Data Collection Center (CDCC); however, given the nature of this data it will not be identifiable or linkable. The CDCC will facilitate cross-site pooling of data, whenever possible, and create a publicly available dataset with this information.",2021-10-17T07:29:58Z,2021-10-17T07:29:58Z,59
NCT04728594,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-26,2021-07-16,NA,2021-07-22,2021-01-26,2021-01-28,Actual,2021-07-22,2021-07-26,Actual,NA,NA,NA,2021-07-22,2021-07-26,Actual,"January 15, 2021",Actual,2021-01-15,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 17, 2021",Actual,2021-01-17,NA,Interventional,NA,"The baseline outcome measure was not applicable, since registration for vaccination was the outcome, and all participants were selected for not being registered.",Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,NA,N/A,9566,Actual,Geisinger Clinic,"In the original ClinicalTrials record, the researchers preregistered that the study would examine primary and secondary outcomes after two days. This was extended to about three days, which was the time when the delayed control group was emailed. This altered timing was dictated by when the organization's marketing department was ready to send emails to the delayed control group.",3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.,The data on the Open Science Framework will be open to anyone requesting that information.,http://osf.io,Yes,Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.,2021-10-17T07:30:37Z,2021-10-17T07:30:37Z,100
NCT04728802,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-27,2021-06-15,NA,2021-06-22,2021-01-27,2021-01-28,Actual,2021-06-15,2021-06-23,Actual,NA,NA,NA,2021-06-22,2021-06-24,Actual,"February 1, 2021",Actual,2021-02-01,June 2021,2021-06-30,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Completed,NA,Phase 3,645,Actual,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Available upon request after peer review and publication.,Available upon request at data@appliedbiology.com,NA,Yes,"Yes, study data sets will be made available upon request after peer review and publication.",2021-10-17T07:30:35Z,2021-10-17T07:30:35Z,130
NCT04724538,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-29,2021-05-02,NA,2021-07-04,2021-01-23,2021-01-26,Actual,2021-07-04,2021-07-07,Actual,NA,NA,NA,2021-07-04,2021-07-07,Actual,"October 15, 2020",Actual,2020-10-15,July 2021,2021-07-31,"March 15, 2021",Actual,2021-03-15,"February 10, 2021",Actual,2021-02-10,NA,Interventional,NA,,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Inhalation Low Dose Radionuclide Therapy in Comprehensive Treatment of COVID-19 Viral Pneumonia,Completed,NA,Phase 1/Phase 2,25,Actual,National Medical Research Radiological Centre of the Ministry of Health of Russia,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:31:13Z,2021-10-17T07:31:13Z,118
NCT04716426,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-18,2021-03-31,NA,2021-04-06,2021-01-18,2021-01-20,Actual,2021-04-06,2021-04-08,Actual,NA,NA,NA,2021-04-06,2021-04-08,Actual,"January 28, 2021",Actual,2021-01-28,April 2021,2021-04-30,"March 25, 2021",Actual,2021-03-25,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,,APTâ„¢ T3X on the COVID-19 Contamination Rate,Use of APTâ„¢ T3X to Decrease the COVID-19 Contamination Rate in Humans,Completed,NA,N/A,100,Actual,University of Nove de Julho,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:32:27Z,2021-10-17T07:32:27Z,207
NCT04698993,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-05,2021-06-16,NA,2021-07-19,2021-01-06,2021-01-07,Actual,2021-06-23,2021-06-25,Actual,NA,NA,NA,2021-07-19,2021-07-20,Actual,"February 12, 2021",Actual,2021-02-12,July 2021,2021-07-31,"March 22, 2021",Actual,2021-03-22,"March 22, 2021",Actual,2021-03-22,NA,Interventional,NA,,DrÃ¤ger COVID-19 Antigen Test Clinical Performance Study,DrÃ¤ger Antigen Test SARS-CoV-2 Clinical Performance Study,Terminated,NA,N/A,388,Actual,DrÃ¤gerwerk AG & Co. KGaA,,2,NA,poor recruitment,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:34:58Z,2021-10-17T07:34:58Z,103
NCT04674644,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-16,2021-01-02,NA,2021-01-30,2020-12-17,2020-12-19,Actual,2021-01-27,2021-01-29,Actual,NA,NA,NA,2021-01-30,2021-02-02,Actual,"October 16, 2020",Actual,2020-10-16,January 2021,2021-01-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department,Completed,NA,N/A,850,Actual,Suleyman Demirel University,"The present study has some limitations. Since the stress and anxiety levels of the dentists participating in the study prior to the pandemic are not known, the extent of the increase in these levels is unknown. In addition, because this is a cross-sectional study, the findings reflect only a certain period of the pandemic. Only scales related to COVID-19 were included, as it was thought that participants might be reluctant to participate in a longer survey.",1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:38:32Z,2021-10-17T07:38:32Z,273
NCT04673214,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-16,2021-03-08,NA,2021-08-12,2020-12-16,2020-12-17,Actual,2021-08-12,2021-08-16,Actual,NA,NA,NA,2021-08-12,2021-08-16,Actual,"December 16, 2020",Actual,2020-12-16,August 2021,2021-08-31,"February 25, 2021",Actual,2021-02-25,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,"Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.",Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20,Completed,NA,Phase 3,114,Actual,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,SHARED VIA EMAIL IF OTHER RESEARCHERS REQUIRE IT,2021-10-17T07:38:44Z,2021-10-17T07:38:44Z,79
NCT04646109,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-15,2020-12-03,NA,2021-01-25,2020-11-25,2020-11-27,Actual,2021-01-25,2021-01-27,Actual,NA,NA,NA,2021-01-25,2021-01-27,Actual,"May 11, 2020",Actual,2020-05-11,January 2021,2021-01-31,"September 2, 2020",Actual,2020-09-02,"September 2, 2020",Actual,2020-09-02,NA,Interventional,NA,"36 patients were included in the study group. But, 6 patients in the study group were excluded from the study and analysis because ivermectin treatments were terminated due to the detection of a mutation that impairs ivermectin metabolism. As a result, overall number of baseline participants in the study group was 30.",Ivermectin for Severe COVID-19 Management,The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management,Completed,NA,Phase 3,66,Actual,Afyonkarahisar Health Sciences University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:42:42Z,2021-10-17T07:42:42Z,278
NCT04634903,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-11,2021-05-18,NA,2021-05-21,2020-11-17,2020-11-18,Actual,2021-05-21,2021-05-25,Actual,NA,NA,NA,2021-05-21,2021-05-25,Actual,"November 19, 2020",Actual,2020-11-19,May 2021,2021-05-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Interventional,NA,,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19",Comparing Two Online Single-Session Interventions for Adolescent Depression: Outcomes of a Randomized Trial,Completed,NA,N/A,2452,Actual,Stony Brook University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Protocol and statistical plan have been posted to Open Science Framework prior to the start of this trial as part of study pre-registration (https://osf.io/kumdv/). Code will be made available upon publication of trial results.,NA,https://osf.io/8mk6x,Yes,NA,2021-10-17T07:44:20Z,2021-10-17T07:44:20Z,162
NCT04610489,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-27,2021-06-28,NA,2021-08-15,2020-10-29,2020-10-30,Actual,2021-08-15,2021-08-17,Actual,NA,NA,NA,2021-08-15,2021-08-17,Actual,"November 13, 2020",Actual,2020-11-13,August 2021,2021-08-31,"March 10, 2021",Actual,2021-03-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,,Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19),Diagnostic Performance of an Antigen Test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Terminated,NA,N/A,117,Actual,Carilion Clinic,,1,NA,Difficulty with recruiting for the study and with staffing the study.,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:48:05Z,2021-10-17T07:48:05Z,76
NCT04599959,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-22,2021-07-21,NA,2021-07-21,2020-10-22,2020-10-23,Actual,2021-07-21,2021-07-26,Actual,NA,NA,NA,2021-07-21,2021-07-26,Actual,"October 26, 2020",Actual,2020-10-26,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,NA,All eligible participants in this study who had been diagnosed with COVID-19 confirmed by polymerase chain reaction (PCR) test within the past 5 days before study entry.,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,"COVID-19 Tests: a Systematic Comparison of Viral RNA Test Sample Taking for RT-qPCR, in This Case With a Nasopharyngeal Swab or Saliva Collected With SalivetteÂ® Cortisol, to Diagnose SARS-CoV-2 Virus Infection",Completed,NA,N/A,151,Actual,Boehringer Ingelheim,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: http://trials.boehringer-ingelheim.com/",2021-10-17T07:49:41Z,2021-10-17T07:49:41Z,101
NCT04596085,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-19,2021-07-29,NA,2021-08-11,2020-10-20,2020-10-22,Actual,2021-08-11,2021-08-12,Actual,NA,NA,NA,2021-08-11,2021-08-12,Actual,"September 16, 2020",Actual,2020-09-16,August 2021,2021-08-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)",Completed,NA,N/A,118,Actual,"The Herb, Inc",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:50:17Z,2021-10-17T07:50:17Z,80
NCT04542694,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-04,2020-10-11,NA,2020-11-03,2020-09-04,2020-09-09,Actual,2020-11-03,2020-11-05,Actual,NA,NA,NA,2020-11-03,2020-11-05,Actual,"May 21, 2020",Actual,2020-05-21,November 2020,2020-11-30,"August 20, 2020",Actual,2020-08-20,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:58:22Z,2021-10-17T07:58:22Z,361
NCT04523831,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-19,2020-09-30,NA,2020-10-07,2020-08-20,2020-08-24,Actual,2020-10-07,2020-10-09,Actual,NA,NA,NA,2020-10-07,2020-10-09,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 10, 2020",Actual,2020-09-10,"August 22, 2020",Actual,2020-08-22,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,"We followed up the patients by telephonic (video) interview, which has some inherent drawback for the study. we could not assess viral clearance directly. Only single dose regimen was used. Efficacy might higher if the different regimen would use.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2021-10-17T08:01:27Z,2021-10-17T08:01:27Z,388
NCT04507867,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-06,2021-09-22,NA,2021-10-13,2020-08-09,2020-08-11,Actual,2021-10-13,2021-10-15,Estimate,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"September 7, 2020",Actual,2020-09-07,October 2021,2021-10-31,"April 10, 2021",Actual,2021-04-10,"April 10, 2021",Actual,2021-04-10,NA,Interventional,NA,"all participants enrolled in the study, a total of 80 patients were compared.",Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Completed,NA,N/A,80,Actual,Anahuac University,"Restriction of resources for laboratory tests, small number of subjects analyzed and restriction of access of measuring instruments to the COVID-19 area.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:03:50Z,2021-10-17T08:03:50Z,17
NCT04502056,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-02,2021-05-28,NA,2021-07-24,2020-08-04,2020-08-06,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"August 7, 2020",Actual,2020-08-07,July 2021,2021-07-31,"September 6, 2020",Actual,2020-09-06,"September 6, 2020",Actual,2020-09-06,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Completed,NA,N/A,20460,Actual,"National Bureau of Economic Research, Inc.","1. It was conducted online, and the participants may not be representative of the population with less than a college degree, since they have access to the internet and are used to participating in online studies; 2. Participants' preventive health behaviors were not directly observed; 3. Outcomes might be subject to social desirability bias.",12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:04:43Z,2021-10-17T08:04:43Z,98
NCT04491994,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,2020-07-31,NA,2020-08-18,2020-07-28,2020-07-30,Actual,2020-08-18,2020-08-21,Actual,NA,NA,NA,2020-08-18,2020-08-21,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-17T08:06:19Z,2021-10-17T08:06:19Z,438
NCT04491240,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-27,2020-10-21,NA,2020-10-28,2020-07-27,2020-07-29,Actual,2020-10-28,2020-11-04,Actual,NA,NA,NA,2020-10-28,2020-11-04,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Interventional,COVID-19EXO,,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:06:25Z,2021-10-17T08:06:25Z,367
NCT04475588,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-16,2020-08-02,NA,2021-06-10,2020-07-16,2020-07-17,Actual,2021-05-17,2021-05-20,Actual,NA,NA,NA,2021-06-10,2021-06-14,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"July 7, 2020",Actual,2020-07-07,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,,Efficacy and Safety of Itolizumab in COVID-19 Complications,"A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications",Completed,NA,Phase 2,32,Actual,Biocon Limited,Due to current pandemic situation few datapoints not available for ptxs who got discharged earlier basis clinical status & bed shortage. As time to discharge was influenced by load on the hospital it was not an evaluable parameter after the trial.,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:08:45Z,2021-10-17T08:08:45Z,142
NCT04463004,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-07,2021-08-04,NA,2021-08-04,2020-07-07,2020-07-09,Actual,2021-08-04,2021-08-11,Actual,NA,NA,NA,2021-08-04,2021-08-11,Actual,"September 2, 2020",Actual,2020-09-02,August 2021,2021-08-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,2,Actual,Virginia Commonwealth University,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:11:21Z,2021-10-17T08:11:21Z,87
NCT04452435,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-29,2021-03-24,NA,2021-06-21,2020-06-29,2020-06-30,Actual,2021-04-28,2021-04-30,Actual,NA,NA,NA,2021-06-21,2021-06-23,Actual,"July 21, 2020",Actual,2020-07-21,June 2021,2021-06-30,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,NA,,Safety and Efficacy of C21 in Subjects With COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation",Completed,NA,Phase 2,206,Actual,Vicore Pharma AB,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:13:53Z,2021-10-17T08:13:53Z,131
NCT04446429,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-22,2021-01-22,NA,2021-06-14,2020-06-23,2020-06-24,Actual,2021-01-29,2021-02-03,Actual,NA,NA,NA,2021-06-14,2021-06-16,Actual,"September 15, 2020",Actual,2020-09-15,June 2021,2021-06-30,"January 21, 2021",Actual,2021-01-21,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,,Anti-Androgen Treatment for COVID-19,Anti-Androgen Treatment for COVID-19,Completed,NA,N/A,268,Actual,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:15:29Z,2021-10-17T08:15:29Z,138
NCT04435808,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-04,2020-08-10,NA,2020-11-12,2020-06-16,2020-06-17,Actual,2020-11-12,2020-11-16,Actual,NA,NA,NA,2020-11-12,2020-11-16,Actual,"April 14, 2020",Actual,2020-04-14,November 2020,2020-11-30,"July 15, 2020",Actual,2020-07-15,"July 15, 2020",Actual,2020-07-15,NA,Interventional,NA,DSMB stopped the study,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2,Terminated,NA,Phase 1/Phase 2,1,Actual,University of New Mexico,,2,NA,Stopped for futility by DSMB,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:08Z,2021-10-17T08:17:08Z,352
NCT04422561,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-06,2020-08-23,NA,2020-08-23,2020-06-06,2020-06-09,Actual,2020-08-23,2020-08-27,Actual,NA,NA,NA,2020-08-23,2020-08-27,Actual,"May 31, 2020",Actual,2020-05-31,August 2020,2020-08-31,"July 27, 2020",Actual,2020-07-27,"July 14, 2020",Actual,2020-07-14,NA,Interventional,NA,,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:19:07Z,2021-10-17T08:19:07Z,433
NCT04421404,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,2021-05-18,NA,2021-08-23,2020-06-05,2020-06-09,Actual,2021-08-23,2021-08-25,Actual,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 9, 2020",Actual,2020-06-09,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,CAPRI,,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients,Completed,NA,Phase 2,34,Actual,"University of California, San Francisco","This study was limited by the small sample of hospitalized, hypoxic patients, limiting the generalizability of the results. Most participants were beyond 72 hours of symptom onset, the period when studies suggest CCP is most likely to be beneficial.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:17Z,2021-10-17T08:19:17Z,68
NCT04411667,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-29,2021-06-10,NA,2021-06-23,2020-06-01,2020-06-02,Actual,2021-06-23,2021-06-25,Actual,NA,NA,NA,2021-06-23,2021-06-25,Actual,"April 28, 2020",Actual,2020-04-28,June 2021,2021-06-30,"June 23, 2020",Actual,2020-06-23,"June 23, 2020",Actual,2020-06-23,NA,Interventional,NA,,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,Completed,NA,Phase 4,34,Actual,Sharp HealthCare,"Study limited to two hospitals in one US city. Resulted in a homogenous population of younger Hispanic/Latino patients.
Study was not blinded.
Methylprednisolone was used as a pre-medication for each dose of IVIG which may have confounded the results.
Small sample size.",2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:43Z,2021-10-17T08:20:43Z,129
NCT04409886,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,2021-05-25,NA,2021-06-25,2020-05-28,2020-06-01,Actual,2021-06-25,2021-06-29,Actual,NA,NA,NA,2021-06-25,2021-06-29,Actual,"June 1, 2020",Actual,2020-06-01,June 2021,2021-06-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,HBOT,,Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients,The Application of Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients - Randomized Controlled Trial,Terminated,NA,Phase 4,1,Actual,Maimonides Medical Center,,1,NA,"This study is part of a larger national study. Only 1 patient was enrolled at Maimonides;
    Medical Center. The study was ended by the sponsor because the PI left; funding ended; , and no
    time, or personnel to do the study",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data will not be shared,2021-10-17T08:21:03Z,2021-10-17T08:21:03Z,127
NCT04410159,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,2020-07-08,NA,2020-07-17,2020-05-28,2020-06-01,Actual,2020-07-17,2020-07-21,Actual,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 29, 2020",Actual,2020-06-29,NA,Interventional,GARGLES,,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,Inadequate budget for laboratory test lead to small numbers of subjects analyzed,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2021-10-17T08:21:00Z,2021-10-17T08:21:00Z,470
NCT04407507,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,2021-05-10,NA,2021-05-19,2020-05-27,2020-05-29,Actual,2021-05-19,2021-05-21,Actual,NA,NA,NA,2021-05-19,2021-05-21,Actual,"July 1, 2020",Actual,2020-07-01,May 2021,2021-05-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,SILVERBULLET,,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms",Completed,NA,Phase 2,66,Actual,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:21:23Z,2021-10-17T08:21:23Z,164
NCT04402970,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-20,2021-03-12,NA,2021-04-12,2020-05-22,2020-05-27,Actual,2021-04-12,2021-04-14,Actual,NA,NA,NA,2021-04-12,2021-04-14,Actual,"June 19, 2020",Actual,2020-06-19,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,DORNASESARS2,,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Completed,NA,Phase 3,30,Actual,University of Missouri-Columbia,Study was performed in non-randomized trial as there were initial concerns for low recruitment and difficulty with randomization. Study was also not powered for most secondary outcome analyses as it was designed in a pilot/feasibility status to determine drug effects.,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:06Z,2021-10-17T08:22:06Z,201
NCT04401579,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,2021-02-25,NA,2021-04-22,2020-05-22,2020-05-26,Actual,2021-04-22,2021-04-26,Actual,NA,NA,NA,2021-04-22,2021-04-26,Actual,"May 8, 2020",Actual,2020-05-08,April 2020,2020-04-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)",Completed,NA,Phase 3,1033,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:19Z,2021-10-17T08:22:19Z,191
NCT04401202,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,2021-05-23,NA,2021-05-25,2020-05-22,2020-05-26,Actual,2021-05-25,2021-05-26,Actual,NA,NA,NA,2021-05-25,2021-05-26,Actual,"May 21, 2020",Actual,2020-05-21,May 2021,2021-05-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,Nigella Sativa in COVID-19,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Completed,NA,Phase 2,183,Actual,King Abdulaziz University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:22:24Z,2021-10-17T08:22:24Z,158
NCT04399980,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,2021-05-06,NA,2021-05-11,2020-05-21,2020-05-22,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"May 20, 2020",Actual,2020-05-20,May 2021,2021-05-31,"April 23, 2021",Actual,2021-04-23,"April 23, 2021",Actual,2021-04-23,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,40,Actual,The Cleveland Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:35Z,2021-10-17T08:22:35Z,172
NCT04392219,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,2021-06-15,NA,2021-07-15,2020-05-15,2020-05-18,Actual,2021-07-15,2021-07-19,Actual,NA,NA,NA,2021-07-15,2021-07-19,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,Safety population,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:47Z,2021-10-17T08:23:47Z,107
NCT04392141,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-15,2020-11-25,NA,2021-04-16,2020-05-15,2020-05-18,Actual,2021-04-16,2021-04-20,Actual,NA,NA,NA,2021-04-16,2021-04-20,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19,Completed,NA,Phase 1/Phase 2,120,Actual,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:51Z,2021-10-17T08:23:51Z,197
NCT04390022,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,2020-12-09,NA,2020-12-10,2020-05-14,2020-05-15,Actual,2020-12-10,2020-12-17,Actual,NA,NA,NA,2020-12-10,2020-12-17,Actual,"July 31, 2020",Actual,2020-07-31,December 2020,2020-12-31,"October 9, 2020",Actual,2020-10-09,"September 17, 2020",Actual,2020-09-17,NA,Interventional,SAINT,,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Completed,NA,Phase 2,24,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:09Z,2021-10-17T08:24:09Z,324
NCT04382066,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,2021-08-02,NA,2021-09-22,2020-05-08,2020-05-11,Actual,2021-09-22,2021-09-24,Actual,NA,NA,NA,2021-09-22,2021-09-24,Actual,"May 12, 2020",Actual,2020-05-12,September 2021,2021-09-30,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,APLICOV-PC,,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization",Completed,NA,Phase 1,46,Actual,PharmaMar,Small number of patients. No control group.,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2021-10-17T08:25:22Z,2021-10-17T08:25:22Z,38
